Thr6

Site Information
__MtEQMtLrGtLkG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18014528

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 )
Disease tissue studied:	cervical cancer ( 5 ) , cervical adenocarcinoma ( 5 ) , melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 2 ) , HeLa S3 (cervical) ( 5 ) , K562 (erythroid) ( 3 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 5 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
4	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
5	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info